Study of Dexmedetomidine Dosages to Reduce Sevoflurane Anesthetic Needs in Children Aged 1 Month to 3 Years

What this Trial Is About

Researchers are studying the effect of two doses of Dexmedetomidine 0.5 mcgkg and 1 mcgkg on the minimum alveolar concentration MAC of Sevoflurane in children aged between 1 month and 3 years. The MAC is the amount of anesthetic needed to prevent movement in half of patients during surgery. Since age affects MAC in children, this study aims to understand how Dexmedetomidine, a sedative with potential neuroprotective properties, influences Sevoflurane dosage in this young population. Participants receive Dexmedetomidine intravenously over 10 minutes before surgery at either 0.5 mcgkg or 1 mcgkg, or a saline placebo, followed by an assigned concentration of Sevoflurane. The trial is randomized and includes multiple groups divided by age ranges 1-6 months, 6-12 months, and 1-3 years. The study compares these dosing regimens to observe the impact on Sevoflurane anesthesia requirements. During the study, researchers monitor participants movement immediately after skin incision to measure anesthetic effect. Safety and response to anesthesia are closely observed, with attention to potential influences on MAC from patient factors or medications. The trial runs until the end of 2025, with detailed assessments during surgery to evaluate how Dexmedetomidine changes Sevoflurane needs in young children.

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane